More news
In the press: Interview in Biotech.info
Ismail CEYLAN, CEO of Advanced BioDesign was interviewed for Biotech.info about our First-In-Man clinical trial ODYSSEY.
Advanced Biodesign receives authorization from ANSM for its “ODYSSEY” Clinical Trial in Acute Myeloid Leukaemia
ODYSSEY is the Phase I First-in-Human clinical trial of drug candidate ABD-3001 in Acute Myeloid Leukaemia (AML) Lyon, 26th January 2022 – Advanced BioDesign, a French biotechnology company specializing in the development of a new group of targeted cancer therapies, has announced that it has received authorization from ANSM (National Agency for Medicinal Safety) and from the CPP (Committee for People Protection) to start its first clinical trial phase for its drug candidate ABD-3001 (a clinical formulation of DIMATE), in Acute Myeloid Leukaemia (AML) and in patients with Myelodysplastic Syndrome (MDS). AML is one of the most common leukaemia among adults, with an occurrence rate in Western countries between 3.7 and 6 per 100,000 inhabitants. Today, the 5-year survival rate among patients over the age of 20 is around 25%, a figure which illustrates the unmet medical needs in this indication.